Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

Inclusion Criteria Patients must have: * Documentation of at least one biopsy-confirmed KS lesion. * A minimum of 4 and no more than 36 KS lesions. * All eligible lesions must be bidimensionally measurable, treatable by surface (non-contact) light illumination, and \<= 40 mm in diameter of the longest bidimensional axis. * ACTG disease state T(0) L(0) or (1) S(0) or (1). * Life expectancy greater than 6 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active opportunistic infection or condition except thrush or herpes simplex virus infections. * Advanced KS tumor stages including the presence of tumor associated edema or ulceration, extensive oral KS, or KS in other non-nodal viscera. * Hematopoietic dysfunction. * Coagulation dysfunction. * Hepatic dysfunction. * Renal dysfunction. * Cardiovascular dysfunction - Presence of significant coronary artery disease requiring current treatment or myocardial infarction. * Pulmonary dysfunction. * Sepsis. * Known disorder of lipoprotein metabolism or clearance. Patients with the following prior conditions are excluded: * History of allergic or hypersensitivity reactions to light, egg proteins or egg yolks, history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum. Excluded within 7 days of therapy: * Hematopoietic dysfunction. * Coagulation dysfunction. * Hepatic dysfunction. * Renal dysfunction. Excluded within 3 months of therapy: * Pulmonary dysfunction. Excluded within 6 months of therapy: * Myocardial infarction. Prior Medication: Excluded: * Intralesional chemotherapy within the past 12 weeks. * Systemic chemotherapy or investigational drugs within the past 4 weeks. Prior Treatment: Excluded within 3 months prior to therapy: * Local cryotherapy or surgery to study lesions. * Systemic or topical photodynamic therapy agents.